Company news
Biogen Inc. news in 2022
Biogen Inc.'s news releases, calls and decks from 2022, newest first.
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
December 18, 2022
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 8, 2022
Biogen Names Christopher Viehbacher President and Chief Executive Officer
November 9, 2022
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
October 16, 2022
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
September 29, 2022
Lecanemab confirmatory phase 3 clarity AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early Alzheimer's disease
September 26, 2022
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
July 25, 2022
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
June 21, 2022
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
June 5, 2022
Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States
June 1, 2022
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 30, 2022
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 4, 2022
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
March 29, 2022
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
March 27, 2022
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
March 15, 2022
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
March 13, 2022
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
February 6, 2022
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
January 31, 2022
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
January 30, 2022
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
January 26, 2022
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
January 3, 2022